On September 10, Carisma Therapeutics and Moderna announced the expansion of their collaboration, including the nomination of two targets for treating autoimmune diseases. These two targets will be exclusively partnered between Carisma and Moderna, with Carisma retaining all rights to autoimmune disease indications outside these nominated targets.Both parties will leverage Carisma's proprietary CAR-M technology and Moderna's mRNA/LNP platform to develop in vivo CAR-M therapies for autoimmune diseases.Carisma Therapeutics will receive research funding and is eligible for development, regulatory, and commercial milestone payments, as well as royalties on net sales of commercialized products. Carisma will be responsible for discovering and optimizing drug candidates, while Moderna will handle the clinical development and commercialization of these drugs.Carisma Therapeutics, Inc. was founded in 2016 and completed its IPO in 2023. Carisma has been dedicated to developing cell therapies using macrophages (CAR-M) for many years.Carisma's engineered cell therapy relies on a breakthrough platform technology that enables genetic manipulation of bone marrow cells, including monocytes and macrophages, in vitro, which are then re-introduced into the patient's body, enabling a variety of therapeutic applications both within and beyond oncology.
Carisma Cell Therapy Platform (Source: Carisma Official Website)
In March 2021, Carisma Therapeutics initiated the world's first patient dosing of CAR-M therapy. This clinical trial (NCT04660929) represents a key milestone in the development of gene therapy, as it is the first study to apply CAR-M therapy in humans.
Carisma Representative Pipeline (Source: Carisma Official Website)
Steven Kelly, President and CEO of Carisma Therapeutics, Inc., stated: "We are delighted to expand our collaboration with Moderna into the field of autoimmune diseases. The nomination of these two autoimmune targets marks a significant milestone in our efforts to leverage macrophage therapy for a broader range of diseases. Our innovative CAR-M technology has the potential to revolutionize the treatment landscape for patients suffering from these conditions."CAR-M is one of the innovative research and development directions in the field of cell therapy. According to PharmaCube NextPharma®Currently, there are nearly 40 CAR-M pipelines under research and development globally, with indications mainly focusing on cancer, while others include systemic amyloidosis, fibrotic diseases, etc. Companies in China that are developing CAR-M cell therapies include Sairun Biotech, Kunshi Biotech, and Yuanmai Cell, among others.References:
https://ir.carismatx.com/news-releases/news-release-details/carisma-and-moderna-expand-collaboration-develop-two-vivo-car-mCopyright © 2024 PHARMCUBE. All Rights Reserved.Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprinting, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
